Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.
|Videos|May 5, 2020
Working With Patients With Heightened Anxiety During COVID-19
Author(s)Yujuan Choy, MD
Yujuan Choy, MD, Chief Psychiatrist at UC Irvine Counseling Center, provides tips for working with patients whose anxiety symptoms disrupt their quality of life.
Advertisement
Yujuan Choy, MD, Chief Psychiatrist at UC Irvine Counseling Center, provides tips for working with patients whose anxiety symptoms disrupt their quality of life.
Dr Choy is past president of the Orange County Psychiatric Society and a distinguished fellow of the American Psychiatric Association. Website:
For more information, see her article,
Advertisement
Related to this article
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
2
Using Psychotherapy for the Prevention of Relapse in Schizophrenia
3
The Adolescent Brain and Schizophrenia: What Research Reveals About Pruning, Dopamine, and Myelin
4
Positive Phase 2 Topline Results: Remlifanserin for the Treatment of Alzheimer Disease Psychosis
5